Background: Metastatic melanoma remains one of the most aggressive forms of cancer, with a survival expectation of above six months only in rare cases. Despite advances in the characterization of the underlying molecular pathways and in the development of specific targeted treatments, available chemo- and immuno-therapy are unable to prolong survival significantly in advanced-stage melanoma. Rai like protein (RaLP) is a newly identified Src homology 2 domain containing (Shc) family member selectively expressed during the transition to metastatic melanoma and thus is a potential melanoma-specific drugable target. Objective: To summarize progress in the ongoing therapeutic approaches to metastatic melanoma and discuss RaLP as a potential novel therapeutic target. Methods: Current understanding of the major signaling pathways involved in melanoma metastatization and of the corresponding pharmacological inhibitors is discussed. Conclusion : RaLP might represent a new drugable target for the treatment of metastatic disease.
Melanoma : targeting signaling pathways and RaLP / L. Pasini, M.Y. Turco, L. Luzi, E. Aladowicz, E. Fagiani, L. Lanfrancone. - In: EXPERT OPINION ON THERAPEUTIC TARGETS. - ISSN 1472-8222. - 13:1(2009 Jan), pp. 93-104.
|Titolo:||Melanoma : targeting signaling pathways and RaLP|
TURCO, MARGHERITA YAYOI (Secondo)
|Parole Chiave:||Metastatic melanoma; RaLP; Shc family; Targeted inhibitors|
|Data di pubblicazione:||gen-2009|
|Digital Object Identifier (DOI):||http://dx.doi.org/10.1517/14728220802607363|
|Appare nelle tipologie:||01 - Articolo su periodico|